Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders ...

Insilico Medicine (“Insilico”) announces that the team, with the support of its generative chemistry engine, has developed a novel and highly selective FGFR2/3 dual inhibitor, which maintains efficacy ...

Experiments in model systems have shown that FGFR-specific inhibitors may be valuable in treating multiple myeloma, bladder and endometrial cancers. FGF1, FGF2 and FGF4 have been studied in ...

CARLSBAD, Calif. - Tyra Biosciences , Inc. (NASDAQ:TYRA), a biotech firm specializing in precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology, today announced the ...

The role of salvage cystectomy after prior trimodality therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not include a full text ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

新京报讯 1月13日，国家药监局网站显示，博珂(厄达替尼片)获批，用于治疗携带易感型FGFR3基因变异，且既往接受至少一线含抗PD-1或抗PD-L1期间或 ...

A 26-residue peptide identified by phage display specifically bound FGF receptor (FGFR) 1c extracellular domain but had no homology with FGFs. When fused with the c-jun leucine zipper domain ...

The green light from the European Commission comes a few months after pan-FGFR inhibitor Balversa (erdafitinib) was cleared for the same indication in the US, with a different label than the drug ...